Nanoscope Therapeutics to Present at the BIO International Convention
29 May 2024
Orphan DrugPhase 2Fast TrackGene Therapy
DALLAS, May 29, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD)AMD), today announced that management will present at the BIO International Convention, taking place June 3-6, 2024, in San Diego, California.
Details for the presentations are as follows:
Session Date: Wednesday, June 5, 2024
Session Time: 4:30 – 4:45 p.m. PT
Location: San Diego Convention Center, Company Presentation Theater 1
Presenter: Sulagna Bhattacharya, Co-Founder and Chief Executive Officer
Ms. Bhattacharya presently serves on the board of directors of BIO. In her presentation, she will highlight Nanoscope's Multi-Characteristic Opsin platform and give an overview of the Company's mutation-agnostic approach. She will also detail the Company's ongoing corporate activities. Nanoscope leadership will be available for meetings during the conference.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company's lead asset, MCO-010, recently announced the 100-week data from the RESTORE Phase 2b/3 multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for RP (NCT04945772). The company has also recently completed the Phase 2 STARLIGHT trial of MCO-010 therapy in patients with Stargardt disease (NCT05417126 ). MCO-010 has received FDA fast-track designations and FDA orphan drug designations for both RP and Stargardt disease. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophies secondary to AMDAMD.
Investor Contact:
Argot Partners
212-600-1902
[email protected]
SOURCE Nanoscope Therapeutics
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.